Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1922-1965
Open Access | Times Cited: 713

Showing 1-25 of 713 citing articles:

Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 864-884
Closed Access | Times Cited: 324
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 12, pp. 1399-1410
Open Access | Times Cited: 190
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
Alessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. e312-e322
Closed Access | Times Cited: 113
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
B. Sangro, Stephen L. Chan, Robin Kate Kelley, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 448-457
Open Access | Times Cited: 110
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 106
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 86
Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 79
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
Sarah Cappuyns, Virginia Corbett, Mark Yarchoan, et al.
JAMA Oncology (2023) Vol. 10, Iss. 3, pp. 395-395
Closed Access | Times Cited: 65
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
Do Young Kim
Journal of Liver Cancer (2024) Vol. 24, Iss. 1, pp. 622-70
Open Access | Times Cited: 48
Development of a liver disease–specific large language model chat interface using retrieval-augmented generation
Jin Ge, Steve Sun, Joseph F. Owens, et al.
Hepatology (2024) Vol. 80, Iss. 5, pp. 1158-1168
Open Access | Times Cited: 43
Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape
Emily N. Kinsey, Hannah M. Lee
Cancers (2024) Vol. 16, Iss. 3, pp. 666-666
Open Access | Times Cited: 38
Latest advances in hepatocellular carcinoma management and prevention through advanced technologies
Tamer A. Addissouky, Ibrahim El Tantawy El Sayed, Majeed M. A. Ali, et al.
Egyptian Liver Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 35
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti, et al.
Ultrasound in Medicine & Biology (2024) Vol. 50, Iss. 8, pp. 1071-1087
Closed Access | Times Cited: 35
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Anju Phoolchund, Salim I. Khakoo
Cancers (2024) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 30
The current landscape of the antimicrobial peptide melittin and its therapeutic potential
Hai-Qian Zhang, Chengbiao Sun, Na Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 30
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
Mohammad Saeid Rezaee‐Zavareh, Yee Hui Yeo, Tielong Wang, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 28
Alpha-fetoprotein: Past, present, and future
Yee Hui Yeo, Yi‐Te Lee, Hsian‐Rong Tseng, et al.
Hepatology Communications (2024) Vol. 8, Iss. 5
Open Access | Times Cited: 22
EASL position paper on clinical follow-up after HCV cure
Thomas Reiberger, Sabela Lens, Giuseppe Cabibbo, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 326-344
Closed Access | Times Cited: 22
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 21
Liver Cancer in 2021: Global Burden of Disease Study
En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 21
Multiparametric MRI for characterization of the tumour microenvironment
Emily Hoffmann, Max Masthoff, Wolfgang G. Kunz, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 428-448
Closed Access | Times Cited: 20
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Abid Suddle, Helen L. Reeves, Richard Hubner, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1235-1268
Open Access | Times Cited: 18
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 13
Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
Subin Heo, Jiwon Yang, Jeayeon Park, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top